Antimicrobial stewardship and drug formulary restrictions during COVID-19: what is restricted and who decides?

Alfredo J. Mena Lora; Rodrigo Burgos; Scott Borgetti; Lelia H. Chaisson; Susan C. Bleasdale

doi:10.1017/ash.2023.205

Antimicrobial Stewardship & Healthcare Epidemiology (Jan 2023)

Antimicrobial stewardship and drug formulary restrictions during COVID-19: what is restricted and who decides?

Alfredo J. Mena Lora,
Rodrigo Burgos,
Scott Borgetti,
Lelia H. Chaisson,
Susan C. Bleasdale

Affiliations

Alfredo J. Mena Lora: University of Illinois at Chicago, Chicago, IL, USA
Rodrigo Burgos: University of Illinois at Chicago, Chicago, IL, USA
Scott Borgetti: ORCiD; University of Illinois at Chicago, Chicago, IL, USA
Lelia H. Chaisson: University of Illinois at Chicago, Chicago, IL, USA
Susan C. Bleasdale: University of Illinois at Chicago, Chicago, IL, USA

DOI: https://doi.org/10.1017/ash.2023.205
Journal volume & issue: Vol. 3

Abstract

Read online

COVID-19 therapies were challenging to deploy due to evolving literature and conflicting guidelines. Antimicrobial stewardship can help optimize drug use. We conducted a survey to understand the role of stewardship and formulary restrictions during the pandemic. Restrictions for COVID-19 therapies were common and approval by infectious disease physicians often required.

Published in Antimicrobial Stewardship & Healthcare Epidemiology

ISSN: 2732-494X (Online)
Publisher: Cambridge University Press
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Infectious and parasitic diseases; Medicine: Public aspects of medicine
Website: https://www.cambridge.org/core/journals/antimicrobial-stewardship-and-healthcare-epidemiology

About the journal

Abstract

Keywords